-
Wall Street set to open higher on tariff relief hopes
-
Russell 2000 (US2000) closes in on 1700 pts resistance once again
-
Twitter (TWTR.US) surges in pre-market trade on strong user numbers
US stocks are set to open higher today after it was reported that China mulls halving of tariffs on some of the US goods. The US economic calendar is light today therefore traders should expect markets to ride the sentiment and remain vulnerable to headline risk. Twitter (TWTR.US) surges in pre-session trading after release of solid user numbers for Q4 2019.
Small-cap Russell 2000 (US2000) recovers in fashion and is trading around 5% higher against the start of the month. The index once again closes in on the resistance zone ranging above 1700 pts mark. As this level was holding firm for a long time, the index may surge once it is finally broken. In such a scenario, attention will shift to ATH in the 1745 pts area. Source: xStation5
Start investing today or test a free demo
Create account Try a demo Download mobile app Download mobile appTwitter (TWTR.US) is surging in pre-session trading. The company reported Q4 earnings. Revenue grew 11% YoY to $1.01 billion, slightly above market consensus. Adjusted EPS of $0.17 was much lower than forecasted $0.28. However, the number of monetizable daily average users was the key highlight of the report. It was expected that this number stood at 148.1 million in Q4 but report showed it at 152 million with bigger than expected increases in the US and abroad. Company said that product improvements were responsible for more than a half of the increase.
Twitter (TWTR.US) is expected to make a big jump at the launch of today’s session. Company reported very strong user numbers. However, even if we take into account a close to 8% jump signalled in pre-session trading the company would still trade below levels from before Q3 earnings release. 200-session moving average (purple) could be a hurdle to watch for this stock today. Source: xStation5
Cardinal Health (CAH.US) is another US company that reported earnings ahead of the opening bell. The US health care company recorded adjusted EPS of $1.52 in fiscal Q2 2020 (calendar Q4 2019), a reading that was higher than expected $1.22 and higher than $1.29 a year ago. Revenue grew 5.3% YoY to $39.74 billion and slightly topped median estimate of $39.41 billion. The company raised guidance for adjusted EPS from continuing operations for fiscal-2020 to $5.20-$5.40 from previous $4.85-5.10.
Bristol-Myers Squibb (BMY.US) reported adjusted EPS for Q4 2019 at $1.22 against an expected $0.94. Revenue came in at $7.95 billion, 28.5% higher than expected. Sales of key cancer drug Opdivo declined 2.5% YoY and 3% QoQ. However, the shortfall was offset by strong performance of other drugs, like Eliquis and Orencia. The company expects full-2020 EPS in the $6.00-6.20 range and full-2020 revenue between $40.5 and $42.5 billion. The Board approved an increase of $5 billion to a share buyback programme.
Cardinal Health (CAH.US) has been trading in a symmetrical wedge pattern as of late. However, thanks to solid earnings release, the stock is set to open above the topside resistance of the pattern. Indicated opening price of $56 would put the stock in a striking distance of November 2019 high ($56.65). Source: xStation5
The content of this report has been created by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, (KRS number 0000217580) and supervised by Polish Supervision Authority ( No. DDM-M-4021-57-1/2005). This material is a marketing communication within the meaning of Art. 24 (3) of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (MiFID II). Marketing communication is not an investment recommendation or information recommending or suggesting an investment strategy within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC and Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest or any other advice, including in the area of investment advisory, within the meaning of the Trading in Financial Instruments Act of 29 July 2005 (i.e. Journal of Laws 2019, item 875, as amended). The marketing communication is prepared with the highest diligence, objectivity, presents the facts known to the author on the date of preparation and is devoid of any evaluation elements. The marketing communication is prepared without considering the client’s needs, his individual financial situation and does not present any investment strategy in any way. The marketing communication does not constitute an offer of sale, offering, subscription, invitation to purchase, advertisement or promotion of any financial instruments. XTB S.A. is not liable for any client’s actions or omissions, in particular for the acquisition or disposal of financial instruments, undertaken on the basis of the information contained in this marketing communication. In the event that the marketing communication contains any information about any results regarding the financial instruments indicated therein, these do not constitute any guarantee or forecast regarding the future results.